News & Updates

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Early initiation of hydroxychloroquine (HCQ) protects patients with cutaneous lupus erythematosus (CLE) from progressing to systemic lupus erythematosus (SLE), a recent study has shown.

Early HCQ treatment prevents progression of CLE to SLE

29 Jun 2025

Tocilizumab with or without MTX for acute RA: Does combo work better than mono?

27 Jun 2025 by

Subcutaneous tocilizumab, used either as a monotherapy or in combination with methotrexate (MTX), shows greater efficacy than MTX alone in Chinese patients with active rheumatoid arthritis (RA) who have not adequately responded to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Tocilizumab with or without MTX for acute RA: Does combo work better than mono?

27 Jun 2025

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

27 Jun 2025 by

Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

27 Jun 2025

Anifrolumab may enhance quality of life in lupus

27 Jun 2025

Patients with systemic lupus erythematosus (SLE) treated with anifrolumab over 4 years appear to report improvements in health status and quality of life, according to data from the TULIP long-term extension trial (TULIP-LTE).

Anifrolumab may enhance quality of life in lupus

27 Jun 2025

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

26 Jun 2025 by

In a post hoc analysis using the phase III REGENCY study dataset, obinutuzumab on top of standard therapy (ST) demonstrates significant superiority to placebo plus ST across numerous renal response definitions in patients with active lupus nephritis (LN).

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

26 Jun 2025

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

New drug applications approved by US FDA as of 16-31 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2025)

23 Jun 2025

Risk of death higher in people with vs without psoriasis

21 Jun 2025

Individuals with psoriatic disease (PsD) are at greater risk of all-cause mortality than those without PsD, reveals a Taiwan study. Specifically, the risk of death is higher in patients with psoriasis but not in those with psoriatic arthritis (PsA).

Risk of death higher in people with vs without psoriasis

21 Jun 2025

Degenerative disc disease in PsA patients tied to old age, back pain, male sex

20 Jun 2025

Young patients with psoriatic arthritis (PsA) are predisposed to degenerative disc disease (DDD), which appears to be associated with demographic features, comorbidities, and disease-related factors, suggests a recent study.

Degenerative disc disease in PsA patients tied to old age, back pain, male sex

20 Jun 2025

IBD tied to increased risk of rheumatoid arthritis

13 Jun 2025

Patients with inflammatory bowel disease (IBD) appear to be at heightened risk of rheumatoid arthritis (RA), as reported in a study.

IBD tied to increased risk of rheumatoid arthritis

13 Jun 2025

Low-dose methotrexate of little benefit in knee OA with effusion-synovitis

09 Jun 2025

In patients with knee osteoarthritis (OA) with effusion, the use of low-dose methotrexate does not appear to relieve pain or reduce effusion-synovitis, as reported in a study.

Low-dose methotrexate of little benefit in knee OA with effusion-synovitis

09 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Early HCQ treatment prevents progression of CLE to SLE

Early HCQ treatment prevents progression of CLE to SLE

Tocilizumab with or without MTX for acute RA: Does combo work better than mono?

Tocilizumab with or without MTX for acute RA: Does combo work better than mono?

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis

Anifrolumab may enhance quality of life in lupus

Anifrolumab may enhance quality of life in lupus

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

Add-on obinutuzumab yields robust treatment benefit in lupus nephritis

Original New Drug Application Approvals by US FDA (16-31 May 2025)

Original New Drug Application Approvals by US FDA (16-31 May 2025)

Risk of death higher in people with vs without psoriasis

Risk of death higher in people with vs without psoriasis

Degenerative disc disease in PsA patients tied to old age, back pain, male sex

Degenerative disc disease in PsA patients tied to old age, back pain, male sex

IBD tied to increased risk of rheumatoid arthritis

IBD tied to increased risk of rheumatoid arthritis

Low-dose methotrexate of little benefit in knee OA with effusion-synovitis

Low-dose methotrexate of little benefit in knee OA with effusion-synovitis